The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete.					
UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL Washington, D.C. 20549 OMB Number: 3235-007 FORM D State of Exempt Offering of Securities					
1. Issuer's Identity					
CIK (Filer ID Number)	Previous Names	None	Entity Type		
0001130166 Name of Issuer Cyclacel Pharmaceuticals, Inc. Jurisdiction of Incorporation/Orga DELAWARE Year of Incorporation/Organization Ver Five Years Ago Within Last Five Years (Specified Science) Yet to Be Formed	ACYTE THE MolecuRx, In CDR Therape Anization Xcyte Therapi On	e. Butics, Inc.	Corporation Limited Partr Limited Liabi General Part Business Tru	lity Company nership ıst	
2. Principal Place of Business a	and Contact Information				
•	00 State/Province/Country NEW JERSEY	Street Address 2 ZIP/PostalCode 07922	Phone Number o 908-517-7330	of Issuer	
3. Related Persons					
Last Name Rombotis Street Address 1 c/o Cyclacel Pharmaceuticals, Inc. City Berkeley Heights Relationship: 📝 Executive Office Clarification of Response (if Nece		puntry	Middle Name ZIP/PostalCode 07922		
Last Name McBarron Street Address 1 c/o Cyclacel Pharmaceuticals, Inc. City Berkeley Heights Relationship: 📝 Executive Office Clarification of Response (if Nece		puntry	Middle Name ZIP/PostalCode 07922		
Last Name Henney Street Address 1 c/o Cyclacel Pharmaceuticals, Inc.	First Name Christopher Street Address 2 200 Connell Drive, State/Province/Co		Middle Name		
City Berkeley Heights Relationship: [Executive Office	State/Province/Co <u>NEW JERSEY</u> cer 📝 Director 🦳 Promote		ZIP/PostalCode 07922		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Barker	Samuel	
Street Address 1	Street Address 2	
c/o Cyclacel Pharmaceuticals, Inc.	200 Connell Drive, Suite 1500	
City	State/Province/Country	ZIP/PostalCode
Berkeley Heights	NEW JERSEY	07922
Relationship: 🔲 Executive Officer 📝 D	irector [🔄 Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Ferguson	Kenneth	
Street Address 1	Street Address 2	
c/o Cyclacel Pharmaceuticals, Inc.	200 Connell Drive, Suite 1500	
City	State/Province/Country	ZIP/PostalCode
Berkeley Heights	NEW JERSEY	07922
Relationship: 🔲 Executive Officer 📝 D	irector 🔲 Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Spiegel	Robert	
Street Address 1	Street Address 2	
c/o Cyclacel Pharmaceuticals, Inc.	200 Connell Drive, Suite 1500	
City	State/Province/Country	ZIP/PostalCode
Berkeley Heights	NEW JERSEY	07922
Relationship: 🔲 Executive Officer 📝 D	irector 🔲 Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Schwartz	Brian	
Street Address 1	Street Address 2	
c/o Cyclacel Pharmaceuticals, Inc.	200 Connell Drive, Suite 1500	
City	State/Province/Country	ZIP/PostalCode
Berkeley Heights	NEW JERSEY	07922
Relationship: 🔲 Executive Officer 📝 D	irector 🔲 Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Walker	Karin	
Street Address 1	Street Address 2	
c/o Cyclacel Pharmaceuticals, Inc.	200 Connell Drive, Suite 1500	
City	State/Province/Country	ZIP/PostalCode
Berkeley Heights	NEW JERSEY	07922
Relationship: 📃 Executive Officer 📝 D	irector 🔲 Promoter	
Clarification of Response (if Necessary):		
4. Industry Group		
Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance		
Investing	Hospitals & Physicians	Computers
Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	
Yes No		Lodging & Conventions

 Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy 	Construction REITS & Finance Residential	 Tourism & Travel Services Other Travel Other 	
5. Issuer Size			
Revenue Range OR No Revenues \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$25,000,000 \$25,000,001 - \$25,000,000 \$25,000,001 - \$25,000,000 \$100,000,000 Over \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable	Aggregate Net Asset Value Rate No Aggregate Net Asset Value \$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable	alue	
6. Federal Exemption(s) and Exclusion(s) Claime	ed (select all that apply)		
 Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) 	 Investment Company Act Section 3(c)(1) Section 3(c)(2) Section 3(c)(3) Section 3(c)(4) Section 3(c)(5) Section 3(c)(6) Section 3(c)(7) 	t Section 3(c) Section 3(c)(9) Section 3(c)(10) Section 3(c)(11) Section 3(c)(12) Section 3(c)(13) Section 3(c)(14)	
7. Type of Filing			
New Notice Date of First Sale 2024-11-14	First Sale Yet to Occur		
8. Duration of Offering			
Does the Issuer intend this offering to last more the			
9. Type(s) of Securities Offered (select all that a	oply)		
 Equity Pooled Investment Fund Interests Debt Tenant-in-Common Securities Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) 			
10. Business Combination Transaction			
Is this offering being made in connection with a bus merger, acquisition or exchange offer?	iness combination transaction, s	uch as a 👘 Yes 📝 No	
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outside inv	vestor \$0 USD		
12. Sales Compensation			
Recipient		\square	

	Recipient CRD Number	
H.C. Wainwright & Co.	00000375	
(Associated) Broker or Dealer 📝 None	(Associated) Broker or Dealer CRD Number 📝 None	
None	None	
Street Address 1	Street Address 2	
430 Park Avenue	4th Floor	
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10022
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
NEW YORK		
13. Offering and Sales Amounts		
Total Offering Amount \$2,062,112 USD or I Indefinite		
Total Amount Sold \$2,062,112 USD		
Total Remaining to be Sold \$0 USD or [] Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold enter the number of such non-accredited investors who alree	t to persons who do not qualify as accredited investors, and eady have invested in the offering.	
Regardless of whether securities in the offering have been	or may be sold to persons who do not qualify as accredited	1
investors, enter the total number of investors who already h	lave invested in the onening.	
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finder an estimate and check the box next to the amount.	is fees expenses, if any. If the amount of an expenditure is no	t known, provide
Sales Commissions \$189,969 USD Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
The Company (a) paid Wainwright an aggregate cash fee of 7% of the g of \$25,000 and (b) issued them warrants to purchase up to 298,137 shar		ense reimbursement
16. Use of Proceeds		
Provide the amount of the gross proceeds of the offering that has be named as executive officers, directors or promoters in respon- the box next to the amount.		
\$0 USD Estimate		
Clarification of Response (if Necessary):		
Signature and Submission		
Please verify the information you have entered and review th to file this notice.	ne Terms of Submission below before signing and clickin	g SUBMIT below
Terms of Submission		
In submitting this notice, each issuer named above is:		
-	s filed of the offering of securities described and undertaking aw, the information furnished to offerees.*	to furnish them,
in which the issuer maintains its principal place of busines process, and agreeing that these persons may accept set such service may be made by registered or certified mail, against the issuer in any place subject to the jurisdiction of activity in connection with the offering of securities that is provisions of: (i) the Securities Act of 1933, the Securities	and, the Securities Administrator or other legally designated of ss and any State in which this notice is filed, as its agents for rvice on its behalf, of any notice, process or pleading, and fur in any Federal or state action, administrative proceeding, or of the United States, if the action, proceeding or arbitration (a the subject of this notice, and (b) is founded, directly or indires s Exchange Act of 1934, the Trust Indenture Act of 1939, the 1940, or any rule or regulation under any of these statutes, or usiness or any State in which this notice is filed.	service of ther agreeing that arbitration brought) arises out of any ectly, upon the Investment

 Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d). Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

	lssuer	Signature	Name of Signer	Title	Date
Cyclacel P	harmaceuticals, Inc.	/s/ Paul McBarron	Paul McBarron	Executive Vice President-Finance, CFO and COO	2024-11-26

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.